ACHV Achieve Life Sciences, Inc.: חוב לטווח קצר של החברה

Achieve Life Sciences (ACHV) specializes in developing innovative treatments for nicotine addiction, aiming to establish cytisine as the gold standard in smoking cessation therapy. This daily price chart reflects the asset's dynamics, while the specific short-term debt metric is recorded at 0.00. However, a liquidity deficit resulting from drug certification costs may increase financial pressure on the company.

Achieve Life Sciences focuses on the global rollout of its nicotine addiction treatment, diversifying clinical trials to mitigate risks. This indicator aggregates all financial obligations due for repayment within the next twelve months. Monitoring this amount allows for an assessment of current solvency and default risk. A reduction in this burden confirms financial stability during the expansion of the therapy. By analyzing the dynamics of short-term debt capital, an investor determines the company's reliance on external financing.